| Home | E-Submission | Sitemap | Editorial Office |  
top_img
Cancer Research and Treatment Search > Browse Articles > Search



EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
Sehhoon Park, Bo Mi Ku, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Se-Hoon Lee, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2020;52(4):1288-1290.   Published online June 22, 2020    DOI: https://doi.org/10.4143/crt.2020.278
                              
Breast cancer
Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis
Ying Lin, Mingxi Lin, Jian Zhang, Biyun Wang, Zhonghua Tao, Yiqun Du, Sheng Zhang, Jun Cao, Leiping Wang, Xichun Hu
Cancer Res Treat. 2020;52(4):1059-1066.   Published online April 24, 2020    DOI: https://doi.org/10.4143/crt.2019.633
                              Supplementary      
RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer
Tian-Hao Weng, Min-Ya Yao, Xiang-Ming Xu, Chen-Yu Hu, Shu-Hao Yao, Yi-Zhi Liu, Zhi-Gang Wu, Tao-Ming Tang, Pei-Fen Fu, Ming-Hai Wang, Hang-Ping Yao
Cancer Res Treat. 2020;52(3):973-986.   Published online April 22, 2020    DOI: https://doi.org/10.4143/crt.2019.726
                              Supplementary         Cited By 2
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies
Myung-Ju Ahn, Ji-Youn Han, Dong-Wan Kim, Byoung Chul Cho, Jin-Hyoung Kang, Sang-We Kim, James Chih-Hsin Yang, Tetsuya Mitsudomi, Jong Seok Lee
Cancer Res Treat. 2020;52(1):284-291.   Published online July 23, 2019    DOI: https://doi.org/10.4143/crt.2019.200
                              
Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
Seulki Kim, Tae Min Kim, Dong-Wan Kim, Soyeon Kim, Miso Kim, Yong-Oon Ahn, Bhumsuk Keam, Dae Seog Heo
Cancer Res Treat. 2019;51(3):951-962.   Published online October 10, 2018    DOI: https://doi.org/10.4143/crt.2018.052
                              Supplementary         Cited By 11
Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
Seonggyu Byeon, Youjin Kim, Sung Won Lim, Jang Ho Cho, Sehoon Park, Jiyun Lee, Jong-Mu Sun, Yoon-La Choi, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2019;51(2):623-631.   Published online July 23, 2018    DOI: https://doi.org/10.4143/crt.2018.151
                              Supplementary         Cited By 9
Impact of Pulmonary Tuberculosis on the EGFR Mutational Status and Clinical Outcome in Patients with Lung Adenocarcinoma
In Kyoung Hwang, Seung Sook Paik, Seung Hyeun Lee
Cancer Res Treat. 2019;51(1):158-168.   Published online April 2, 2018    DOI: https://doi.org/10.4143/crt.2018.084
                              Supplementary         Cited By 1
EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
Jiyoul Yang, Ok-Jun Lee, Seung-Myoung Son, Chang Gok Woo, Yusook Jeong, Yaewon Yang, Jihyun Kwon, Ki Hyeong Lee, Hye Sook Han
Cancer Res Treat. 2018;50(3):908-916.   Published online September 19, 2017    DOI: https://doi.org/10.4143/crt.2017.378
                                 Cited By 11
Incorporating Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Place of Neutrophil Count and Platelet Count Improves Prognostic Accuracy of the International Metastatic Renal Cell Carcinoma Database Consortium Model
Pawel Chrom, Rafal Stec, Lubomir Bodnar, Cezary Szczylik
Cancer Res Treat. 2018;50(1):103-110.   Published online March 3, 2017    DOI: https://doi.org/10.4143/crt.2017.033
                              Supplementary         Cited By 14
Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer
Youngjoo Lee, Ki Hyeong Lee, Geon Kook Lee, Soo-Hyun Lee, Kun Young Lim, Jungnam Joo, Yun Jung Go, Jin Soo Lee, Ji-Youn Han
Cancer Res Treat. 2017;49(4):1001-1011.   Published online January 13, 2017    DOI: https://doi.org/10.4143/crt.2016.546
                                 Cited By 13
Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status
Youngjoo Lee, Ji-Youn Han, Sung Ho Moon, Byung-Ho Nam, Kun Young Lim, Geon Kook Lee, Heung Tae Kim, Tak Yun, Hye Jin An, Jin Soo Lee
Cancer Res Treat. 2017;49(4):981-989.   Published online January 6, 2017    DOI: https://doi.org/10.4143/crt.2016.522
                              Supplementary         Cited By 3
Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis
Sook-Hee Hong, Yeon-Sil Kim, Ji Eun Lee, In-ho Kim, Seung Joon Kim, Daehee Han, Ie Ryung Yoo, Yang-Guk Chung, Young-Hoon Kim, Kyo-Young Lee, Jin-Hyoung Kang
Cancer Res Treat. 2016;48(3):1110-1119.   Published online January 6, 2016    DOI: https://doi.org/10.4143/crt.2015.289
                                 Cited By 5
The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo
Keun-Yong Eom, Bong Jun Cho, Eun Jung Choi, Jin-Ho Kim, Eui Kyu Chie, Hong-Gyun Wu, Il Han Kim, Sun Ha Paek, Jae-Sung Kim, In Ah Kim
Cancer Res Treat. 2016;48(2):687-697.   Published online June 4, 2015    DOI: https://doi.org/10.4143/crt.2014.320
                                 Cited By 14
Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea
Jaemin Jo, Jung Ho Kim, Ji Young Kim, Changlim Hyun, Jiyoung Rhee, Jungmi Kwon, Sanghoon Han, Wookun Kim
Cancer Res Treat. 2016;48(1):393-397.   Published online February 17, 2015    DOI: https://doi.org/10.4143/crt.2014.209
                              
A New Approach to the Treatment of Metastatic Paraganglioma: Sorafenib
Meral Gunaldi, Ismail Oguz Kara, Berna Bozkurt Duman, Cigdem Usul Afsar, Melek Ergin, Arbil Avci
Cancer Res Treat. 2014;46(4):411-414.   Published online July 18, 2014    DOI: https://doi.org/10.4143/crt.2013.093
                                 Cited By 1
Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Bhumsuk Keam, Dong-Wan Kim, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Doo Hyun Chung, Dae Seog Heo
Cancer Res Treat. 2014;46(4):323-330.   Published online July 14, 2014    DOI: https://doi.org/10.4143/crt.2013.120
                                 Cited By 13
Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Jae Cheol Lee, Seung Hun Jang, Kye Young Lee, Young-Chul Kim
Cancer Res Treat. 2013;45(2):79-85.   Published online June 30, 2013    DOI: https://doi.org/10.4143/crt.2013.45.2.79
                                 Cited By 12
Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer
D. Nathan Kim, Taek-Keun Nam, Kevin S. Choe, Hak Choy
Cancer Res Treat. 2012;44(2):74-84.   Published online June 30, 2012    DOI: https://doi.org/10.4143/crt.2012.44.2.74
                                 Cited By 4
Korean Cancer Association
E-Submission
EndNote Output Style
Email Alert
Impact factor
SCImago Journal & Country Rank
PubMed Central
MEDLINE/PubMed
Scopus
KoreaMed
KoMCI
ScienceCentral
GoogleScholar
Similarity Check
Crossref Cited-by Linking
CrossMark
Funder Registry
ORCID
COPE
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association. All rights reserved.                 Developed in M2Community